Abstract
Multiple myeloma (MM) is a clonal neoplasm characterized by expansion of malignant plasma cells in the bone marrow causing various complications including osteolytic lesions and impaired immune function. It has recently been reported that human myeloma cells express multiple Toll-like receptors (TLRs), and their activation-induced functional responses show heterogeneity among cell lines and patient samples. TLRs are critical germ-line encoded molecules expressed in immune cells as well as in a variety of cancer cells. In multiple myeloma, they may induce cell growth and proliferation or promote cell death. In fact, our current knowledge of Toll-like receptor function has gone beyond their main function as triggers of innate and adaptive immune responses. Considering the essential role of bone marrow microenvironment components in myeloma tumor expansion, survival, invasion and drug resistance, TLR triggering may contribute to adhesion-induced or de novo drug resistance of MM cells. Future preclinical and clinical studies are needed to address if TLRs can be exploited as novel therapeutic targets for MM.
Keywords: Bone marrow, drug resistance, inflammation, multiple myeloma, toll like receptors.
Current Molecular Medicine
Title:Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis
Volume: 14 Issue: 4
Author(s): J. Abdi, J. Garssen and F. Redegeld
Affiliation:
Keywords: Bone marrow, drug resistance, inflammation, multiple myeloma, toll like receptors.
Abstract: Multiple myeloma (MM) is a clonal neoplasm characterized by expansion of malignant plasma cells in the bone marrow causing various complications including osteolytic lesions and impaired immune function. It has recently been reported that human myeloma cells express multiple Toll-like receptors (TLRs), and their activation-induced functional responses show heterogeneity among cell lines and patient samples. TLRs are critical germ-line encoded molecules expressed in immune cells as well as in a variety of cancer cells. In multiple myeloma, they may induce cell growth and proliferation or promote cell death. In fact, our current knowledge of Toll-like receptor function has gone beyond their main function as triggers of innate and adaptive immune responses. Considering the essential role of bone marrow microenvironment components in myeloma tumor expansion, survival, invasion and drug resistance, TLR triggering may contribute to adhesion-induced or de novo drug resistance of MM cells. Future preclinical and clinical studies are needed to address if TLRs can be exploited as novel therapeutic targets for MM.
Export Options
About this article
Cite this article as:
Abdi J., Garssen J. and Redegeld F., Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis, Current Molecular Medicine 2014; 14 (4) . https://dx.doi.org/10.2174/1566524014666140414204100
DOI https://dx.doi.org/10.2174/1566524014666140414204100 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intracellular Trafficking of Plasmids for Gene Therapy: Mechanisms of Cytoplasmic Movement and Nuclear Import
Current Gene Therapy Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response
Current Molecular Medicine A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Targeting P-glycoprotein for Effective Oral Anti-Cancer Chemotherapeutics
Current Cancer Drug Targets EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Kavalactone Pharmacophores for Major Cellular Drug Targets
Mini-Reviews in Medicinal Chemistry Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells
Current Medicinal Chemistry Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Current Medicinal Chemistry Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds The Influence of Traumatic Lumbar Puncture (TLP) on Outcome of Pediatric Patients
Current Pediatric Reviews Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Pulmonary Arterial Hypertension
Current Vascular Pharmacology Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation
Current Pharmaceutical Design Advances in the Management of Malignant Hemopathies: The Role of Statins
Recent Patents on DNA & Gene Sequences Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design